Rationale: Plasminogen activator inhibitor-1 (PAI-1) is a biomarker for several vascular disease states; however, its target of action within the vessel wall is undefined. Objective: Determine the ability of PAI-1 to regulate myoendothelial junction (MEJ) formation. Methods and Results: MEJs are found throughout the vasculature linking endothelial cells (ECs) and vascular smooth muscle cells. Using a vascular cell coculture we isolated MEJ fractions and performed two-dimensional differential gel electrophoresis. Mass spectrometry identified PAI-1 as being enriched within MEJ fractions, which we confirmed in vivo. In the vascular cell coculture, recombinant PAI-1 added to the EC monolayer significantly increased MEJs. Conversely, addition of a PAI-1 monoclonal antibody to the EC monolayer reduced the number of MEJs. This was also observed in vivo where mice fed a high fat diet had increased PAI-1 and MEJs and the number of MEJs in coronary arterioles of PAI-1 ؊/؊ mice was significantly reduced when compared to C57Bl/6 mice. The presence of MEJs in PAI-1 ؊/؊ coronary arterioles was restored when their hearts were transplanted into and exposed to the circulation of C57Bl/6 mice. Application of biotin-conjugated PAI-1 to the EC monolayer in vitro confirmed the ability of luminal PAI-1 to translocate to the MEJ. Functionally, phenylephrine-induced heterocellular calcium communication in the vascular cell coculture was temporally enhanced when recombinant PAI-1 was present, and prolonged when PAI-1 was absent. Conclusion: Our data implicate circulating PAI-1 as a key regulator of MEJ formation and a potential target for pharmacological intervention in diseases with vascular abnormalities (eg, diabetes mellitus). (Circ Res. 2010;106: 1092-1102.)
I n diseases that exhibit vascular abnormalities, increased circulating plasminogen activator inhibitor-1 (PAI-1) is considered a major biomarker; however its function in these diseases remains unclear. [1] [2] [3] [4] [5] In the vasculature, fibrinolysis and the plasminogen activator (PA) system are regulated by PAI-1 through inhibition of urokinase PA (uPA) and tissue PA (tPA), 6, 7 maintaining an important balance between matrix degradation and cellular adhesion. Inhibition of PAs disrupts the activation of plasminogen into plasmin, negatively regulating localized matrix degradation and maintaining a stable scaffold for cells to adhere to. 2,8 -10 Decreases in PAI-1 results in excessive proteolytic activity and increased matrix degradation, creating an unstable extracellular matrix (ECM) scaffold which disrupts cellular attachment and thereby the invasion by endothelial cell (EC) extensions into the ECM. Conversely, large increases in PAI-1 can inhibit overall matrix degradation, preventing the growth of EC extensions into the ECM. 11, 12 Therefore, the enzymatic balance of proteolytic activity and its regulation by PAI-1 is important in the formation of EC cellular extensions. 11, 13, 14 In the resistance vasculature, EC extensions that penetrate the ECM-rich internal elastic lamina (IEL) form myoendothelial junctions (MEJs), which are locations within a vessel where ECs establish heterocellular contact or apposition with vascular smooth muscle cells (VSMCs). [15] [16] [17] The MEJ is unique to the resistance vasculature and hypothesized to be a highly organized cell-signaling microdomain that facilitates heterocellular communication between ECs and VSMCs (for review see 18 ) . Several additional studies correlate changes in MEJ regulation with multiple vascular pathologies such as diabetes mellitus, where changes in the vasoreactivity of diseased vessels are associated with potential changes in the number of MEJs. 18 -21 Despite the suggested importance of MEJs in the maintenance of vasomotor tone, there are currently no documented mechanisms regarding the regulation of MEJ formation and their potential role in vascular pathologies.
To test the hypothesis that PAI-1 can regulate MEJ formation we isolated in vitro MEJs and determined the enriched expression of PAI-1 at the MEJ and confirmed its presence at the MEJ in vivo. Modulation of PAI-1 activity at the EC luminal surface was reflected by changes in both in vitro and in vivo MEJ formation, where increases in PAI-1 augmented the number of MEJs and decreased PAI-1 activity had the opposite effect. Heterocellular communication between the two cell types, presumably occurring at the MEJ was also affected in response to changes in PAI-1 activity. We therefore suggest that circulating PAI-1 regulates MEJ formation and can alter heterocellular signaling mediated through MEJs in the resistance vasculature.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mice
Wild-type mice, strain C57Bl/6 and PAI-1 Ϫ/Ϫ mice, strain B6.129S2-Serpine1 tm1Mlg /J, were males 8 to 10 weeks of age and used according to the University of Virginia Animal Care and Use Committee guidelines. Mice used for high fat comparison were C57Bl/6 mice fed a caloric-rich diet (5.45 kcal/g, 0.2% cholesterol, 35.5% fat; Bio-Serv).
Vascular Cell Coculture
Vascular cell cocultures were assembled as described. 22 Cells were derived from human umbilical vein (Cell Applications, Inc, San Diego) and grown in M199 (Gibco) supplemented with 10% FBS (Gibco), 1% glutamine (Gibco), 1% penicillin/streptomycin (Gibco), EC media also contained endothelial cell growth supplement (5 g/mL, BD Biosciences); Additional cell lines were derived from human coronary artery (Lonza Walkersville Inc). Endothelial cells were grown in EBM-2 MV (Lonza) supplemented with Lonza bullet kits (Lonza), VSMCs were grown in SmBM (Lonza) supplemented with Lonza bullet kits (Lonza). Seeding densities of 7.5x10 4 VSMCs and 3.6x10 5 ECs were used.
Recombinant PAI-1 (rPAI-1) (0.1 g/mL; Technoclone) and PAI-1 monoclonal antibody (mAb) (10 g/mL; Technoclone) were added every 24 hours to ECs 48 hours before isolation. Biotinconjugated rPAI-1 (Cell Sciences) was added to ECs 30 minutes before isolation.
Isolation of MEJ Fractions
Following 6 days in culture, VSMC monolayers were scraped into lysis buffer and repeated for EC monolayers. The MEJ fractions were collected by removing the denuded Transwell membranes into lysis buffer, and vortexing. All fractions were sonicated and spun at 2500 rpm for 5 minutes and the supernatant collected. All steps were performed at 4°C.
Immunoblots
Protein fractions were run on 10% SDS-PAGE Gels, transferred to nitrocellulose and imaged on a Li-Cor Odyssey Imager. 23
Antibodies and Protein
Secondary antibodies: phalloidin conjugated to Alexa 488 or Alexa 594, donkey anti-rabbit or donkey anti-mouse Alexa 488 or Alexa 594, all from Invitrogen. Goat anti-rabbit or anti-mouse IRDye 680 or 800CW was used for immunoblots (Li-cor Biosciences). Primary antibodies: SM␣-actin (monoclonal, Sigma); VE-cadherin, uPA and tPA (all polyclonal, Santa Cruz Biotechnologies), GAPDH (mono-clonal, Zymed), PAI-1 polyclonal (Abcam), PAI-1 monoclonal (immunoblot analysis, BD Biosciences), Cx37 and Cx40 (polyclonal, ADI), Cx43 (polyclonal, Sigma) Cx45 (polyclonal, kind gift of Steinberg, Washington University 24 ), anti-rabbit 10 nm gold beads were from The Jackson Laboratory.
2D-DIGE Analysis
Individual protein fractions were labeled with Cy2, Cy3 or Cy5 and run per manufacturer specifications (Amersham BioSciences). IPG strips were transferred into gradient SDS-Gel (9% to 12% SDS). Image scans were made using Typhoon TRIO (Amersham Bio-Sciences), analyzed by Image QuantTL software (GE-Healthcare). The ratio change of protein differential expression was obtained by in-gel DeCyder software analysis.
Mass Spectrometry
Proteins of interest were digested in-gel and MALDI-TOF MS and TOF/TOF tandem MS/MS were performed. Peptide mass and associated fragmentation spectra were searched in the National Center for Biotechnology Information nonredundant (NCBInr) database. Candidates with protein score confidence interval percent (C.I.%) or Ion C.I.% greater than 95 were considered significant.
Immunostaining
Immunohistochemistry on the vascular cell coculture (VCCC) was performed as described. 22 
Quantification of MEJs Using the VCCC
The number of F-actin filled pores per micrometer was quantified using Metamorph (Universal Imaging Corps, version 7.5.6.0). Phalloidin staining visualized F-actin within pores of the Transwell.
Immunolabeling on TEM Sections
Visualization of proteins by TEM was performed as described. 25 Quantification of electron-dense gold-beads was performed by immunolabeling for PAI-1 with minimum 5 TEM images per coronary arteriole, 10 m apart. The areas of each component (EC, MEJ, and VSMC) were quantified using Metamorph software calibrated to measuring area (m 2 ). The EC and VSMC monolayers were traced from apical to basal lateral membrane. For MEJs, cellular extensions penetrating the IEL were defined by a line across the basal lateral membrane from which the MEJ originated, dissecting the junction from the monolayer, tracing the extension through the IEL to the base of the adjacent basal lateral membrane. The area inside these lines defined the area of the MEJ. The number of gold beads in each area (EC, MEJ, or VSMC) was counted. Measurements represent the average number of beads per micron squaredϮSE. 
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Quantification of PAI-1 on Actin Bridges In Vivo
Quantification of PAI-1 on actin bridges formed between ECs and VSMCs in vivo was performed as previously described. 25
Ultrastructure Electron Microscopy
Coronary arterioles were fixed in 4% paraformaldehyde and 2% gluteraldehyde at 4°C and ultrastructural TEM images were obtained as described. 3 We quantified the total number of MEJs within a vessel using a minimum of 5 TEM images per coronary arteriole. To quantify the radial length of a vessel, a single line was traced along the EC basal lateral membrane with this distance measured using calibrated Metamorph software. Cellular extensions that penetrated the traced EC basal lateral membrane, IEL and came within Ͻ250 nm of membranous contact between ECs and VSMCs was counted as one MEJ. Numbers represent the average number of MEJs per 10 m radial length Ϯ SE. A minimum radial diameter of 150 mm per mouse and 10 m between each TEM section were used.
Heart Transplants
Heart transplants were performed as described (see Online Figure  I ). 26 Five days postsurgery, donor hearts were harvested for TEM.
Recombinant PAI-1 Tail Vein Injections
Fifty microliters (L) of rPAI-1 (1000 ng/g) or saline was injected into PAI-1 Ϫ/Ϫ mice via lateral tail vein every 12 hours for five days. Tissue was harvested for TEM.
Calcium Imaging
Fura-2 acetoxymethyl ester was loaded onto EC and VSMC monolayers as described for Fluo-4 acetoxymethyl ester (see Online Figure II ). 27 The VSMCs were stimulated with 10 mol/L phenylephrine (PE) and EC intracellular calcium concentrations [Ca 2ϩ ] i were recorded as described. 27 
Statistics
Significance for all experiments was at PϽ0.05 and determined by one-way ANOVA (Bonferroni post hoc test); error bars are ϮSE using Origin Pro 6.0 software.
Results
Isolation and Characterization of MEJ Proteins
For initial experiments demonstrating isolation of EC, VSMC, and MEJ protein fractions we used phalloidin to mark cellular components of the VCCC. In Figure 1A and 1D, an intact VCCC with cell monolayers and actin extensions within the pores of the Transwell (eg, in vitro MEJs 22 ) is clearly observed. The formation of junctions is also confirmed by expression of vascular specific connexins in isolated VSMC, EC, and MEJ fractions (as previously described 22 and Online Figure III ). After the EC and VSMC monolayers were removed by scraping, the actin extensions within the Transwell pores remained ( Figure 1B and 1E ). When the scraped membranes were vortexed with lysis buffer, in vitro MEJs were no longer visible via phalloidin staining ( Figure 1C and 1F). The three fractions were analyzed via silver stain ( Figure 1G ) and GelCode Blue ( Figure  1H ), demonstrating an abundance of proteins in each fraction. Immunoblots demonstrated labeling of MEJ and EC fractions for VE-Cadherin ( Figure 1I ) and SM␣-actin labeling of VSMC and MEJ fractions ( Figure 1J ), with equivalent loading for all three fractions ( Figure 1K ). These data demonstrate our ability to isolate in vitro MEJs from the VCCC. Simultaneous comparison of isolated in vitro VSMC, EC, and MEJ fractions was performed using 2D-DIGE proteomic analysis. Representative images compare EC and VSMC fractions (Figure 2A son between each fraction of the same spot. Using Qualitative DeCyder analysis, all spots with increased protein expression in the MEJ fraction were identified. Of these, three spots (arrows 1 to 3) of similar molecular weight and pH had greater than 2.5 fold increase in protein expression in the MEJ fraction as compared to VSMC and EC fractions (Figure 2A ). Using DeCyder software, spots 1 to 3 are represented quantitatively as protein expression peaks, where each spot is identified by a magenta tracer ( Figure 2B ). Mass spectrometry identified each of these spots as PAI-1, with minimal 99.9% confidence in protein identification ( Figure 2C ). It is likely, although not confirmed that each spot represents a separate glycosylation isoform of PAI-1. Results were confirmed using coronary artery EC, VSMC, and MEJ fractions (Online Figure IV) .
PAI-1 at the MEJ
To verify expression of PAI-1 at the MEJ in vitro, we immunoblotted isolated VSMCs, EC and MEJ fractions and showed enrichment of PAI-1 in MEJ fractions ( Figure 3A ).
Using confocal microscopy to image transverse sections of the VCCC, we also confirmed the expression of PAI-1 in the pores of the VCCC membrane, where PAI-1 colocalized with F-actin regardless of it's location in the Transwell pores ( Figure 3B ). Associated substrates for PAI-1, active and inactive uPA, but not tPA, were increased in MEJ fractions (Online Figure V) , supporting our identification of PAI-1 at the MEJ in vitro. Quantified immunohistochemistry of whole mount tissue preps from fixed C57Bl/6 and PAI-1 Ϫ/Ϫ mesenteric, cremasteric and coronary microvascular beds labeled for PAI-1 confirm the presence of PAI-1 on actin bridges in vivo ( Figure 3C ). Quantified immunolabeling for PAI-1 on TEM sections of C57Bl/6 coronary arterioles showed expression of PAI-1 at the MEJ in vivo ( Figure 3D , as well as mesenteric and cremasteric arterioles, Online Figure VI) .
The presence of PAI-1 is crucial for invasion of EC extensions into the ECM. 13 To determine whether PAI-1 is similarly necessary for the formation of MEJs, we depleted PAI-1 activity in each monolayer using a PAI-1 specific mAb or increased PAI-1 activity using rPAI-1. Depletion of activity caused a significant reduction in MEJs, but only when applied to EC or EC/VSMC monolayers ( Figure 4A and Online Figure VII) . Likewise, addition of rPAI-1 caused a significant increase in MEJs only in the EC and EC/VSMCtreated monolayers ( Figure 4B and Online Figure VII) . The identification of PAI-1 was corroborated in coronary artery cells with immunoblots for PAI-1 at the MEJ as well as changes in MEJ formation in response to changes in PAI-1 (Online Figure VII) .
To verify the ability of PAI-1 to regulate MEJ formation in vivo, we performed TEM ultrastructure analysis on coronary arterioles isolated from C57Bl/6 and PAI-1 Ϫ/Ϫ mice. Vessels from C57Bl/6 mice had significantly more MEJs (Figure 5A and 5I) than those from PAI-1 Ϫ/Ϫ mice ( Figure 5B and 5I ). This was also demonstrated in mesenteric and cremasteric arterioles (Online Figure VIII) . Conversely, coronary arterioles isolated from C57Bl/6 mice fed a high fat diet had increased PAI-1 expression (Online Figure IX) and signifi- cantly more MEJs (Figure 5C and 5I) as compared to C57Bl/6 mice fed a standard chow diet. To test whether circulating PAI-1 could enhance MEJ formation in vivo, we performed heterotypic heart transplants. Transplantation of a C57Bl/6 heart into a C57Bl/6 mouse ( Figure 5D ) or a PAI-1 Ϫ/Ϫ heart into a PAI-1 Ϫ/Ϫ mouse ( Figure 5E ) produced no change in MEJ formation ( Figure 5A , 5B, 5I, respectively). However, PAI-1 Ϫ/Ϫ hearts transplanted into a C57Bl/6 mouse, increased MEJ formation similar to that seen in C57Bl/6 mice ( Figure 5F and 5I ). This data further suggests that circulating PAI-1 interacts with ECs to influence formation of MEJs. To verify that increases in MEJ formation were attributable to increases in PAI-1, we injected saline or rPAI-1 into PAI-1 Ϫ/Ϫ mice via tail vein, to increase circulating PAI-1 (Online Figure X) . Saline injected PAI-1 Ϫ/Ϫ mice showed no change in MEJ formation ( Figure 5G ) when compared to noninjected PAI-1 Ϫ/Ϫ (Figure 5A , 5B, and 5I). Increases in circulating PAI-1 (injected rPAI-1) produced similar increases in MEJ formation ( Figure 5H ) as compared to those seen following the heart transplants and C57Bl/6 mice ( Figure 5A , 5E, and 5I) suggesting changes in MEJ formation are likely attributable to PAI-1.
To determine whether exposing the EC luminal surface to increased PAI-1 could result in relocation of PAI-1 to the MEJ, we applied biotin-conjugated rPAI-1 to the VSMC or EC monolayers of the VCCC thirty minutes before isolation. Following application of biotin-conjugated rPAI-1 to the VSMCs the rPAI-1 could not be detected with streptavidin in the MEJ fractions, nor in the controls (Figure 6A through 6D) . However, when applied to the EC monolayer, the biotin conjugated rPAI-1 was readily detected at the MEJ (Figure 6A, 6B , and 6E). The sum of the data suggests that increased PAI-1 results in the movement of PAI-1 from the lumen to the MEJ.
Effects of PAI-1 on Ca 2؉ Signaling at the MEJ
To test the functional effect of changes in the number of MEJs as a result changes in PAI-1 activity in vitro, we measured heterocellular Ca 2ϩ communication from the VSMCs to the ECs by stimulating VSMCs with PE ( Figure 7A ). Following stimulation of the VSMCs with PE, there were no changes in the maximum EC Ca 2ϩ response regardless of EC treatment with rPAI-1(ϩrPAI-1) or mAb to PAI-1(-PAI-1). The addition of gap junction blocker glycyrrhetinic acid (ϩGA) or inhibiting MEJ formation through collagen coating of the Transwell (Online Figure XI) significantly decreased the EC Ca 2ϩ response ( Figure 7B ). However, the addition of rPAI-1 to the EC monolayer resulted in a more rapid increase in EC Ca 2ϩ as compared to EC monolayers with depleted PAI-1 (-PAI-1; Figure 7C and 7D). None of the conditions altered the expression of vascular connexins at the MEJ (Online Figure XII) . These data suggest that PAI-1 can enhance heterocellular communication, which is likely a result of increased MEJ formation.
Discussion
In the present study we provide evidence for the biomarker PAI-1 in the regulation of MEJ formation and function. Plasminogen activator inhibitor-1 is the major regulator of the PA system. Components of the PA system, uPA and tPA activate plasminogen to plasmin, which degrades ECM. Specifically, inhibition of uPA by PAI-1 decreases matrix degradation, maintaining a localized area of structured matrix scaffold to facilitate cellular invasion of EC extensions into the ECM. 11, 28, 29 Because of its role in the formation of cellular extensions and regulation of matrix degradation, disruption of the balance between PA components, namely changes in PAI-1 activity, can result in decreased cellular invasion. In the resistance vasculature, cellular invasion by the ECs or VSMCs is required for functional MEJs to form. The disruption of MEJ function has been indirectly implicated in vascular diseases such as diabetes mellitus 19 -21 ; however, no studies regarding regulation of MEJ formation have been reported.
To identify regulatory proteins enriched at the MEJ, we developed a method for isolating in vitro MEJ fractions using the VCCC as an in vitro model of the MEJ. 22, 27, 30 Isolation of specific EC, VSMC, and MEJ protein fractions was confirmed using immunoblot analysis for cell-type specific markers, which not only demonstrated successful isolation of each monolayer, but isolation of the EC and VSMC components of the MEJ as well. This is the first time that MEJs have been directly isolated, either in vivo or in vitro and we believe this method will enhance the capacity to investigate the function of MEJs. Although a method to isolate protein from MEJs in vivo would be ideal, thus far any method to isolate and characterize MEJs outside of immunohistochemistry, usually using TEM (eg, elsewhere 16 ), has proven elusive.
Using simultaneous 2D-DIGE analysis, we identified three spots representing proteins with increased expression in the MEJ (in vitro) as compared to ECs and VSMCs and using mass spectrometry these spots were determined to be PAI-1. Expression of PAI-1 at the MEJ was confirmed both in vitro using confocal microscopy and in vivo using TEM. Because all three spots from the 2D-DIGE were found at the same molecular weight but demonstrated different isoelectric focusing, it is possible that each spot represents one of the glycosylated isoforms of PAI-1. 31 It has been suggested that the glycosylation state of PAI-1 may be useful in determining the protein's origin 32 and further investigation regarding the glycosylated isoforms of PAI-1 could provide insight for the origin of PAI-1 expressed at the MEJ in vivo.
Because of the ability of PAI-1 to regulate matrix degradation and cellular adhesion to the ECM, it is considered an integral component of EC invasion into the ECM. 11 We therefore tested the hypothesis that MEJ formation mimics EC invasion of the ECM as regulated by PAI-1. Using the VCCC, increases in PAI-1 activity (by addition of rPAI-1) promoted an increase in the number of actin extensions (ie, in vitro MEJs) that formed. Conversely depletion of endogenous PAI-1 activity (using a mAb specific for PAI-1) decreased the number of actin extensions, suggesting PAI-1 plays a critical role in the formation of MEJs. Correlating with these data, TEM analysis of isolated PAI-1 Ϫ/Ϫ arterioles demonstrated significantly less MEJs as compared to C57Bl/6 mice. Ultrastructure analysis also revealed a thicker IEL in the knockout vessels as compared to wild type. These data are in agreement with recent evidence that shows PAI-1 Ϫ/Ϫ cells exhibit increased collagen production, which correlates with an increase in TGF-␤ activity through sustained activation by integrins. 33 Plasminogen activator inhibitor-1 is a biomarker for several vascular disease states, including diabetes 1,3-5,34 -36 which is also associated with the dysregulation of MEJs. 18 In C57Bl/6 mice fed a high fat diet there is a significant increase in body weight, blood glucose and PAI-1 levels, effectively mimicking diabetic conditions (Online Figure IX) . Isolated coronary arterioles from these mice have significantly more MEJs and decreased IEL thickness as compared to the C57Bl/6, so we determined if increases in circulating PAI-1 were capable of regulating MEJ formation in vivo using heterotypic heart transplants. When hearts from PAI-1 Ϫ/Ϫ mice were transplanted into a C57Bl/6 mouse and exposed to circulating PAI-1, MEJ formation within PAI-1 Ϫ/Ϫ coronary arterioles was significantly increased five days post surgery. We confirmed that changes in circulating PAI-1 affected MEJ formation by injecting rPAI-1 into PAI-1 Ϫ/Ϫ mice, demonstrating an increase in MEJ formation in isolated coronary arterioles similar to that seen in PAI-1 Ϫ/Ϫ vessel transplanted into a C57Bl/6 and C57Bl/6 controls. Evidence shows that increases in available PAI-1 coincides with increased cellular invasion 37 and our data supports a similar mechanism, whereby increases in MEJ formation occur in response to circulating PAI-1.
Application of rPAI-1 in vitro and heterotypic heart transplants suggest for the first time that increases in PAI-1 at the EC luminal membrane can effect MEJ formation. The application of biotin-conjugated rPAI-1 demonstrated the translocation of biotin-conjugated rPAI-1 from the luminal surface of ECs to the MEJ and further supports the hypothesized movement of PAI-1. It is well documented that VSMCs produce PAI-1 38, 39 and it is likely that some of the endogenous PAI-1 expressed at the MEJ is VSMC-derived, however, the application of biotin-conjugated rPAI-1 to the VSMC monolayer showed no increase in PAI-1 at the MEJ, which coincides with experiments that show with application of mAb or rPAI-1 to the VSMC monolayer there is no change in the number of MEJs in vitro. Therefore, our data indicates that in conditions where circulating PAI-1 is increased, changes in MEJ formation are mediated through the movement of circulating PAI-1 from the luminal surface of ECs to the IEL. Although the internalization of PAI-1 for degradation occurs via a low density lipoprotein receptor mediated mechanism was first described in 1992 40, 41 , there is currently no defined mechanism for the uptake and translocation of circulating PAI-1 to areas of the IEL and subsequent sites of potential MEJ formation.
As a unique signaling microdomain, the MEJ is hypothesized to play a key role in the regulation of heterocellular Ca 2ϩ signaling (reviewed elsewhere 18 ). Modulation of PAI-1 activity in vitro using rPAI-1 or mAb to PAI-1 showed no variation in the maximal EC Ca 2ϩ responses following PE stimulation of VSMCs. This indicated that the ECs could still respond normally to second messengers that are produced in the VSMCs and move through gap junctions at the MEJ (eg, elsewhere 30, 42 ). However, there was a significant difference in the rate of Ca 2ϩ response between VCCCs treated with rPAI-1 and those with depleted PAI-1, correlating with an increase or decrease (respectively) in the number of MEJs (Figure 7) . We interpret these data to mean that the number of MEJs, specifically gap junctions at the MEJ, dictates the time necessary for ECs to respond to second messengers from the VSMCs.
In concurrence with our Ca 2ϩ data and the observed effects of PAI-1 on MEJ formation, we would hypothesize that mice deficient in PAI-1 have impaired vasoreactivity to agonist stimulation caused by a reduced number of MEJs. Indeed, it was recently reported that mesenteric artery rings from Figure 6 . Uptake and expression of biotin-conjugated rPAI-1 at the MEJ. Immunoblots of VSMC, MEJ, and EC fractions isolated from the VCCC stained with streptavidin. Three experimental paradigms were tested: no application of biotinconjugated rPAI-1, application of biotin-conjugated rPAI-1 (0.1 g) to the VSMC monolayer and application of biotinconjugated rPAI-1 (0.1 g) to only the EC monolayer. GAPDH is shown directly below each condition (A). Normalized quantification of protein expression for biotin-conjugated rPAI-1 for each fraction and experimental paradigm is given in B. Immunocytochemistry on transverse sections of the VCCC for biotinconjugated rPAI-1 using streptavidin (green) and F-actin (with phalloidin, red) for the following experimental paradigms: no application of biotin-conjugated rPAI-1, application of biotinconjugated rPAI-1 (0.1 g) to the VSMC monolayer and application of biotin-conjugated rPAI-1 (0.1 g) to only the EC monolayer). For all images, VCCC were treated 30 minutes before isolation. Bar in C is 10 m and representative for images (C and D). *PϽ0.05. For A and B, nϭ4.
PAI-1 Ϫ/Ϫ mice have diminished sensitivity to acetylcholine (R. Korthuis, University of Missouri, Columbia, unpublished data, 2009). It is also well documented that in multiple diabetic models with upregulated PAI-1, there is increased sensitivity to vasoconstrictors (eg, PE). [43] [44] [45] [46] Our data supports this hypothesis, providing a potential mechanism for how PAI-1 may affect vasoreactivity through changes in MEJ formation. However, it is important to note that despite increasing evidence supporting a role for MEJs in pathological conditions, it is still unknown if these changes are compensatory or promoting the disease state.
In conclusion, after isolating proteins expressed at the MEJ and performing 2D-DIGE analysis, we have identified PAI-1, an important mediator of ECM degradation and major biomarker for several vascular diseases, as being enriched at the MEJ. Our data suggests localization of PAI-1 to the MEJ allows it to act as a key regulator of MEJ formation and function. The increase or decrease in MEJs in response to changes in PAI-1, including conditions that mimic diabetes, correlate with altered temporal Ca 2ϩ responses in ECs following VSMC stimulation. Although this article does not present a mechanism for how PAI-1 regulates MEJ formation, it is the first evidence of a protein inducing the formation of MEJs, as is extensively demonstrated using innovative techniques both in vitro and in vivo. Although it remains to be seen if the changes in MEJ formation during vascular disease are beneficial, the accumulation of this work suggests that manipulation of PAI-1 at the MEJ may be an attractive pharmaceutical target to treat vascular associated diseases where heterocellular communication is aberrant. The maximum values of EC [Ca 2ϩ ] i following PE stimulation is quantified, and conditions include application of PAI-1 (ϩrPAI-1); application of rPAI-1 plus glycyrrhetinic acid (ϩrPAI-1ϩGA); control; controlϩGA, decreases in PAI-1 using a mAb against PAI-1 (-PAI-1); decreases in PAI-1 plus glycyrrhetinic acid (-PAI-1ϩGA); and no MEJs (B). In C, the temporal change in EC [Ca 2ϩ ] i after stimulation of VSMC with PE following application of rPAI-1 (ϩrPAI-1), control; decreases in (-PAI-1); and no MEJs are shown. The time required to reach maximum EC [Ca 2ϩ ] i fluorescent intensity after VSMC stimulation with PE is shown for each condition: application of rPAI-1 (ϩrPAI); control; and decreases in PAI-1 (-PAI-1) (D). For all images, VCCCs were treated for the final 48 hours of culture, *PϽ0.05; nϭ3 Transwells per experimental condition.
